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We evaluated garenoxacin potency in selection of Streptococcus pneumoniae resistance 
compared to other quinolones, by determining the mutant prevention concentration, using 
strains with and without topoisomerase genes mutations. Garenoxacin is potently active 
against pneumococci including topoisomerase mutations-containing strains, at a level 
significantly greater than other quinolones. The genetic analysis of S. pneumoniae mutants 




The emergence of Streptococcus pneumoniae strains with resistance to the -lactams and 
macrolides has complicated the treatment of pneumococcal respiratory tract infections and 
created a need for new agents. Recently developed compounds within the quinolone group 
have demonstrated enhanced potency against S. pneumoniae. In particular, agents such as 
moxifloxacin, gatifloxacin, and levofloxacin have been recommended and used for therapy 
(16). However, S. pneumoniae strains exhibiting quinolone resistance have been observed in 
several countries (3,9,11,15,18). Furthermore, evidence suggests that increased usage of these 
compounds could lead to further resistance development and treatment failure (5,7,19).  
Quinolone resistance in S. pneumoniae is mediated by amino acid substitutions within the 
quinolone resistance determining regions (QRDRs) of DNA gyrase (GyrA or GyrB) and/or 
topoisomerase IV (ParC or ParE), sometimes in combination with efflux (1,12,14).  
The mutant prevention concentration (MPC), the drug concentration that prohibits the growth 
of mutants from a susceptible population of more than 1010 cells, is a novel approach in the 
evaluation of FQ potency (2). Additionally, mutant selection window (MSW), which is 
defined as the range between MIC and MPC, provides a means of defining the ability of 
antibiotics in preventing the emergence of mutants (21). 
Garenoxacin (GAR) is a novel des-F(6) quinolone with a broad spectrum of activity against 
respiratory tract pathogens, including S. pneumoniae with elevated resistant-level 
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fluoroquinolone MIC values (4,10,13,20). The aim of this study was to evaluate GAR potency 
in selection of S. pneumoniae resistance compared to other quinolones, by determining the 
MPC and the MSW, using strains with and without mutations of QRDR in topoisomerase 
genes. Additionally, we examined the intrinsic development of S. pneumoniae resistant 
mutants created by garenoxacin exposure, with detailed evaluation of additional QRDR 
mutations and efflux, for determining the target of GAR.  
 
Materials and Methods 
A total of eight S. pneumoniae clinical isolates were used in this study. QRDR genetic 
backgrounds and quinolones MICs of isolates are summarized in Table 1. All strains were 
wild-type with GyrB and with ParE. Isolates W001 and W002 are quinolone-susceptible 
isolates with wild-type ParC and GyrA. An isolate S001 have a Asp83Asn mutation in ParC 
with wild-type GyrA. An isolate S002 have a Ser79Phe mutation in ParC with wild-type 
GyrA. Isolates S003 and S004 have a GyrA single mutation (Ser81Phe in S003 and Gly85Asn 
in S004). Isolates D001 and D002 have both GyrA and ParC mutations (D001; Ser79Phe in 
ParC and Gly85Lys in GyrA, D002; Ser79Phe in ParC and Ser81Phe in GyrA).  All strains 
were exposed to two, four, eight, sixteen, thirty-two, and sixty-four times the MICs of 
ciprofloxacin (CIP), levofloxacin (LVX), gatifloxacin (GAT), moxifloxacin (MXF), and GAR 
for 48 hr to 72 hr of incubation at 37C in 5%CO2.  The MPCs were measured with the 
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procedure previously described (2). Briefly, 200l of a culture containing 10 log10 CFU/ml 
was applied to Mueller Hinton II Agar plates containing 5% sheep blood and drugs at various 
concentrations. MPCs were recorded as the lowest antibiotic concentration that prevented 
bacterial colony formation at 48 hr. All determination was done in duplicate, and the results 
were identical.  
Genomic DNA was extracted from growing mutants (maximum eight mutants per one plate 
were purely cultured, see Table 2) using QIAGEN® Blood Mini Kit (QIAGEN, Hilden, 
Germany). All DNA extracts of mutants were screened for possessing QRDR mutations of 
parC and gyrA genes using a novel PCR-melting curve analysis (PCR-MCA) method which 
we previously reported (8). Briefly, probes labeled with LC-Red 640 and fluorescein were 
used with designated primers (8), which targeting four QRDR positions (Ser79 and Asp83 of 
the parC gene and also Ser81 and Gly85 of the gyrA gene). PCR was performed in a total 
volume of 20 μl containing 5 μl of DNA template, 4 μl of LightCycler® 480 Genotyping 
Master (Roche Diagnostics, Basel, Switzerland), 3mM MgCl2, 0.2 μM each probes, and 0.5 
μM each primers. Thermal cycling was performed with an initial hold for 10 min at 95ºC, 
followed by 35 cycles of 5 sec at 95ºC, 10 sec at 55ºC and 12 sec at 72ºC. Melting curve was 
generated by cooling to 40ºC for 30 sec, followed by heating to 80ºC at a rate of 2.0ºC/s. The 
PCR-MCA assay was performed using LightCycler480® analysis software (Roche 
Diagnostics, Basel, Switzerland). The total assay time was approximately 1 hr. Nucleotide 
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mismatches between the sequence and the hybridization probe result in a lower mutant 
melting temperature (Tm) than that of the wild-type.  The assay makes it possible to quickly 
and easily differentiate a mutant strain from a wild-type strain. 
The QRDR sequence of topoisomerase genes (parC, parE, gyrA, and gyrB) of mutant strains 
were confirmed by all directly sequenced at the nucleotide level using the BigDye® 
Terminator ver.3.1 Sequencing Standard Kit and an ABI PRISMTM 310 Genetic Analyzer 
(both by Applied Biosystems, CA, USA) with published primers (17). The QRDR DNA 
sequencing results were compared with the strain R6 (GenBank accession no. NC_003098).  
MIC determination was done in parallel both with or without an efflux inhibitor (10g of 




The MPCs and MSW ranges of S. pneumoniae isolates were summarized in Figure 1. The 
MPCs which shown were averaged between W001 and W002, S001 and S002, S003 and 
S004, D001 and D002.  The MPC order in S. pneumoniae strains was CIP > LVX > GAT ≥ 
MXF > GAR. GAR potency was 16- to 64-fold greater than LVX or CIP, and 4-fold superior 
to GAT or MXF. GAR had a significantly narrow MSW compared to other quinolones, even 
against strains with QRDR mutations. Compared between strains, MSW range was, wild-type 
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strains (W001 and W002)  strains with QRDR single mutation (S001-004)  strains with 
double QRDR mutations (D001 and D002). Strains with parC single mutation showed narrow 
MSW compared to strains with gyrA single mutation which exposed to LVX, GAT and GAR, 
while CIP and MXF were in reverse. Number of pneumococcal picked up mutants which 
created by GAR exposure were shown in Table 2. QRDR wild-type strains created mutants 
with GAR exposure from MIC to 8MICs, while strains with QRDR mutations created 
mutants from MIC to 16-32MICs. QRDR genetic changes in S. pneumoniae mutants created 
by GAR exposure were shown in Table 3.  Results of PCR-MCA assay of mutants from 
wild-type strains (W001 and W002) created by GAR exposure revealed high percentage of 
additional gyrA mutations. With regard to the strains with parC single mutation (S001 and 
S002), high percentages of additional gyrA mutation in codon 81 was seen.  On the other 
hand, strains with gyrA single mutation (S003 and S004), additional parC mutation in codon 
79 was seen in high percentage. Strains with double QRDR mutations (D001 and D002) 
showed additional gyrA mutaions resulted from GAR exposure. None of the mutants created 
from GAR exposure showed existence of efflux, by MIC determination with reserpine. DNA 
sequence analysis using mutants without additional QRDR mutations with GAR exposure, 
showed two mutants from W001, and one mutant from W002 with additional parE mutation 
(Asp435Asn). In addition, two mutants from W001, one mutant from W002, two mutants 
from S003, and one mutant from S004 showed additional parC mutation (Lys137Asn). With 
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In the present study, the MIC results showed that GAR was potently active against 
pneumococci including QRDR mutations-containing strains, at a level significantly greater 
than other quinolones. In addition, significantly narrow range of MSW, and the low MPC 
values demonstrated that pneumococcus hard to acquire resistance to GAR, compared to other 
quinolones. 
We used an original PCR-MCA assay to enable a detailed genetic analysis of QRDR 
mutations using vast numbers of mutants.  This was difficult in previous studies due to the 
time-consuming nature of analyzing the DNA sequence of mutants.   
A high proportion of the mutants that were from isolates with a parC single mutation acquired 
secondary mutations in gyrA and became highly resistance to all of the quinolones we used in 
our study. With regard to wild type pneumococcal strains, the high percentage of additional 
GyrA mutations was seen in GAR-exposed mutants. This may indicate that GAR may have a 
more balanced affinity for the two target enzymes, with a slight initial preference for GyrA as 
an initial target. 
A total of 72 out of 231 mutants (31%) were not detected of additional gyrA or parC 
 10
mutations in this study. These remaining mutants were expected to acquire additional other 
QRDR mutations (parE or gyrB) or efflux, however, only ten mutants (14) were detected by 
the sequence of topoisomerase genes. These mutants may have acquired other resistant 
mechanisms, such as plasmid-based resistance. Further studies are needed to clarify 
pneumococcal resistant mechanisms to GAR.  
Although quinolone resistance in S. pneumoniae isolates remains low, the opportunity for the 
treatment of respiratory tract infections rises. The potential for resistance formation should 
thus be considered when specific fluoroquinolones are selected for treatment. Including MPCs 
as part of a dosing strategy may be one means of limiting the selection of quinolone-resistant 
mutants and preserving this class of antibiotic. 
In conclusion, a novel des-F(6) quinolone, Garenoxacin showed the low MPC value and the 
narrow MSW for QRDR mutation containing pneumococcal strains, suggested that will be 
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Figure 1.   Levels of Mutant Prevention Concentrations and Mutant Selection Windows of S. pneumoniae Strains
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